Business
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted for presentation at EASL 2023 highlight the latest data from pipeline in hepatitis B and hepatitis D viruses -- SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present data from its herpes simplex virus (HSV), hepatitis D virus (HDV) and hepatitis B virus (HBV) pipeline programs at upcoming medical congresses. Assembly Bio’s abstract for ABI-5366 has been accepted for oral and poster presentation at the International Herpesvirus Workshop, taking place in Missoula, Montana, July 15-19, 2023. Five abstracts have been accepted for poster presentation at the International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna, Austria, June 21-24, 2023, including one poster presentation selected for inclusion in the Best of EASL Congress summary. International Herpesvirus Workshop 2023For the first time, Assembly Bio will present data highlighting the preclinical characterization of ABI-5366, a long-acting HSV helicase inhibitor targeting high-recurrence genital herpes and the company’s first development candidate for herpesviruses. “We are excited to present these data describing ABI-5366’s compelling preclinical profile, including low nanomolar potency in vitro against both HSV-1 and HSV-2, the potential for long-acting oral administration and non-GLP safety data to date showing that the candidate has been well tolerated,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “High-recurrence genital herpes remains an important unmet need that has not had a significant therapeutic advancement in decades. We continue to actively progress our IND-enabling studies, with initiation of GLP toxicity studies targeted for early Q3 2023, and we expect to enter the clinic in the first half of next year.” Details of the presentations are as follows: ABI-5366: Oral and Poster Presentation: Pre-clinical characterization of ABI-5366: a highly potent long-acting helicase-prim...